17 Analysts Have This To Say About Boston Scientific
Portfolio Pulse from Benzinga Insights
17 analysts have provided mixed ratings for Boston Scientific (NYSE:BSX), with a recent shift towards more bullish perspectives. The average 12-month price target is now $69.24, marking a 10.78% increase from the previous target. Analysts have adjusted their ratings and price targets, reflecting optimism about the company's performance. Boston Scientific, known for its less invasive medical devices, has shown a positive revenue trend with a 14.9% growth rate as of December 31, 2023, but faces challenges in ROE and ROA compared to industry averages.
March 07, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific has received mixed but increasingly bullish ratings from 17 analysts, with an updated average 12-month price target of $69.24. The company's positive revenue growth and strong market presence are highlighted, despite facing some challenges in ROE and ROA.
The increase in the average price target to $69.24, along with the positive revenue growth of 14.9% as of December 31, 2023, suggests optimism about Boston Scientific's financial health and market position. However, the challenges in ROE and ROA indicate areas of concern that could temper the bullish sentiment. The mixed but increasingly bullish ratings from analysts reflect a positive outlook on the stock, likely leading to a short-term positive impact on its price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100